Literature DB >> 22592806

Linking surveillance with action against drug-resistant tuberculosis.

Ted Cohen1, Justin Manjourides, Bethany Hedt-Gauthier.   

Abstract

The speed at which most countries with high burdens of multidrug-resistant tuberculosis (MDRTB) have scaled up their capacity to diagnose and treat individuals with these forms of TB has failed to keep pace with the problem. Limited availability of drug susceptibility testing, high costs and inefficiencies in the supply of second-line drugs, and inadequate capacity for the management of patients with MDRTB have contributed to the wide gap between the estimated need for and the delivery of MDRTB treatment. The most recent global estimates indicate that only about 1 in 20 individuals with incident MDRTB will be properly diagnosed; fewer still receive quality-assured treatment. As policy makers confront the threat of growing levels of drug-resistant TB, there is a clear role for improved surveillance methods that can facilitate more effective public health responses. In countries that cannot yet test all incident cases for drug resistance, analysis of programmatic data and use of periodic, efficient surveys can provide information to help prioritize the use of limited resources to geographic areas or population subgroups of greatest concern. We describe methods for the analysis of routinely collected data and alternative surveys that can help tighten the link between surveillance activities and interventions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592806      PMCID: PMC3443807          DOI: 10.1164/rccm.201203-0394PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  19 in total

1.  The interpoint distance distribution as a descriptor of point patterns, with an application to spatial disease clustering.

Authors:  Marco Bonetti; Marcello Pagano
Journal:  Stat Med       Date:  2005-03-15       Impact factor: 2.373

2.  Antituberculosis drug resistance in the south of Vietnam: prevalence and trends.

Authors:  Nguyen T Huong; Nguyen T N Lan; Frank G J Cobelens; Bui D Duong; Nguyen V Co; Maarten C Bosman; Sang-Jae Kim; Dick van Soolingen; Martien W Borgdorff
Journal:  J Infect Dis       Date:  2006-09-18       Impact factor: 5.226

Review 3.  Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus".

Authors:  P Farmer; J Y Kim
Journal:  BMJ       Date:  1998-09-05

4.  Non-parametric estimation of spatial variation in relative risk.

Authors:  J E Kelsall; P J Diggle
Journal:  Stat Med       Date:  1995 Nov 15-30       Impact factor: 2.373

Review 5.  Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease.

Authors:  D L Cohn; F Bustreo; M C Raviglione
Journal:  Clin Infect Dis       Date:  1997-01       Impact factor: 9.079

6.  Challenges in estimating the total burden of drug-resistant tuberculosis.

Authors:  Ted Cohen; Caroline Colijn; Abigail Wright; Matteo Zignol; Alexander Pym; Megan Murray
Journal:  Am J Respir Crit Care Med       Date:  2008-03-27       Impact factor: 21.405

7.  Anti-tuberculosis drug resistance and HIV co-infection in Phnom Penh, Cambodia.

Authors:  Borann Sar; Chantary Keo; Chanthy Leng; Manil Saman; Doung Chan Min; Sarin Chan; Didier Monchy; Jean-Louis Sarthou
Journal:  Southeast Asian J Trop Med Public Health       Date:  2009-01       Impact factor: 0.267

8.  Cluster detection methods applied to the Upper Cape Cod cancer data.

Authors:  Al Ozonoff; Thomas Webster; Veronica Vieira; Janice Weinberg; David Ozonoff; Ann Aschengrau
Journal:  Environ Health       Date:  2005-09-15       Impact factor: 5.984

9.  Method for mapping population-based case-control studies: an application using generalized additive models.

Authors:  Thomas Webster; Verónica Vieira; Janice Weinberg; Ann Aschengrau
Journal:  Int J Health Geogr       Date:  2006-06-09       Impact factor: 3.918

10.  Are survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation study.

Authors:  Ted Cohen; Caroline Colijn; Bryson Finklea; Abigail Wright; Matteo Zignol; Alexander Pym; Megan Murray
Journal:  PLoS One       Date:  2008-06-04       Impact factor: 3.240

View more
  5 in total

1.  Spatially targeted screening to reduce tuberculosis transmission in high-incidence settings.

Authors:  Patrick G T Cudahy; Jason R Andrews; Alyssa Bilinski; David W Dowdy; Barun Mathema; Nicolas A Menzies; Joshua A Salomon; Sourya Shrestha; Ted Cohen
Journal:  Lancet Infect Dis       Date:  2018-12-13       Impact factor: 25.071

2.  Geographical heterogeneity of multidrug-resistant tuberculosis in Georgia, January 2009 to June 2011.

Authors:  H E Jenkins; M Gegia; J Furin; I Kalandadze; U Nanava; T Chakhaia; T Cohen
Journal:  Euro Surveill       Date:  2014-03-20

Review 3.  Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Authors:  William A Wells; Catharina C Boehme; Frank G J Cobelens; Colleen Daniels; David Dowdy; Elizabeth Gardiner; Jan Gheuens; Peter Kim; Michael E Kimerling; Barry Kreiswirth; Christian Lienhardt; Khisi Mdluli; Madhukar Pai; Mark D Perkins; Trevor Peter; Matteo Zignol; Alimuddin Zumla; Marco Schito
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

4.  Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country.

Authors:  Helen E Jenkins; Valeriu Plesca; Anisoara Ciobanu; Valeriu Crudu; Irina Galusca; Viorel Soltan; Aliona Serbulenco; Matteo Zignol; Andrei Dadu; Masoud Dara; Ted Cohen
Journal:  Eur Respir J       Date:  2012-10-25       Impact factor: 16.671

5.  Use of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya.

Authors:  Julia Jezmir; Ted Cohen; Matteo Zignol; Edwin Nyakan; Bethany L Hedt-Gauthier; Adrian Gardner; Lydia Kamle; Wilfred Injera; E Jane Carter
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.